OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study Jan 18, 2018
OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab Dec 14, 2017
OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform Nov 28, 2017
OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017 Nov 9, 2017
OncoSec Announces Positive Updated Long-Term Follow-Up Data from Phase 2 Trial of ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Progression Free Survival Rate (PFS) of 57% at 15 months in Predicted Anti-PD-1 Non-Responder Melanoma Patients Nov 8, 2017
